Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 88 Pages
|Zontivity(急性冠狀動脈症候群)- 預測與市場分析 Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023|
|出版日期: 2014年07月31日||內容資訊: 英文 88 Pages||
GlobalData has released its new PharmaPoint Drug Evaluation report, "Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023". The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.
Under normal circumstances, thrombin proteolytically processes the platelet surface receptor protein PAR1, which initiates a strong platelet-activating, pro-thrombotic, signal transduction pathway. Zontivity locks the PAR1 receptor into a conformation that prevents thrombin recognition, thereby halting platelet activation and thrombosis at this key step. Of the several receptor-mediated platelet activation pathways, the PAR1 route results in a particularly strong platelet activation response.